Teva Chief Seeks Growth Beyond $40.5 Billion Allergan Deal
- Israeli company may target specialty assets next, CEO says
- Enlarged business has 338 treatments awaiting FDA approval
This article is for subscribers only.
Teva Pharmaceutical Industries Ltd.’s $40.5 billion purchase of Allergan Plc’s generics unit, which closed Tuesday, doesn’t signal that the Israeli drugmaker will let up its quest for innovative branded medicines.
Efforts to introduce new copycat drugs and integrate operations gained through its largest acquisition “doesn’t mean we confine our business to just generics,” Chief Executive Officer Erez Vigodman said in an interview at Teva’s headquarters in Petach Tikva, Israel. “The strategy and vision are much broader.”